Keytruda® (pembrolizumab) – Accelerated approval to full approval
December 16, 2022 - The FDA approved Merck’s Keytruda (pembrolizumab), for an alternate dosing regimen of 400 mg every six weeks for all approved adult solid tumor indications.
Download PDF
